Our findings show that EV-derived proteins (PDIA3, BTN1A1, APRIL) and complement-associated proteins could be further explored in myeloma, as biomarkers across disease natural history and as potential new drug targets that could be monitored by PB sampling. The gene discussed is PDIA3; the disease is plasma cell myeloma.